Astellas, Sanofi, Lundbeck up for innovation award; Lilly launches online molecule board game;

> Astellas' Dificlir, Sanofi's ($SNY) Lemtrada and Lundbeck's Selincro are a few of the contenders up for the 2014 Innovative Drug Award. Report

> IMS Health has announced it intends to acquire certain Cegedim information solutions and Customer Relationship Management businesses for €385 million ($520 million) in cash. Release

> Forest Laboratories' ($FRX) Viibryd performed significantly better than a placebo for treating generalized anxiety disorder, three late-stage studies show. Report

> Alexion ($AXLN) and Cincinnati Children's Hospital Medical Center have announced the establishment of a collaboration and fund for the advancement of research in rare disease. Release

> A University of Tokyo investigation panel found 'serious faults' in a Novartis ($NVS) significant input of company employees in the trial's planning stages. More

And Finally... Eli Lilly's ($LLY) new online board game, "Destination Discovery," helps users experience the challenges of "bringing a new medicine from molecule to medicine cabinet." More

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Acadia Pharmaceuticals is taking Parkinson’s disease education on the road in a partnership with the Michael J. Fox Foundation.

AbbVie continues its long-running aggressive TV ad push for Humira last month, while Gilead Sciences takes two spots in the top 10 tally from iSpot.